Agoracom Blog Home

Archive for the ‘Medical Marijuana Stocks’ Category

« Older Entries
Newer Entries »

BREAKING: Namaste $N.ca $NXTTF Receives ACMPR Medical #Cannabis Production License $ATT.ca $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Posted by AGORACOM-JC at 4:04 PM on Friday, March 16th, 2018

Nlogo

  • Wholly owned subsidiary, Cannmart has received its Access to Cannabis for Medical Purposes Regulations Production License
  • Cannmart may now place initial orders with ACMPR licensed producers
  • Confident in its ability to execute and complete the final steps towards receiving its Sales License in a timely manner
  • With receipt of the production license, Namaste now expects to execute on its overall vision of becoming an all-inclusive online cannabis marketplace

VANCOUVER, British Columbia, March 16, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that its wholly owned subsidiary, Cannmart Inc. (“Cannmart”) has received its Access to Cannabis for Medical Purposes Regulations (“ACMPR”) Production License (the “License”). Under the guidelines set forth by Health Canada, Cannmart may now place initial orders with ACMPR licensed producers. Upon receipt, packaging and testing of the initial shipments of medical cannabis, the Company is then required to demonstrate compliance with standard operating procedures (“SOPs”) and other ACMPR regulatory requirements with Health Canada. Once these objectives have been achieved and following an initial inspection, Cannmart will be able to book a Pre-Sales License Inspection after which the Company will be eligible to receive its ACMPR Sales License. Cannmart believes it is well prepared and confident in its ability to execute and complete the final steps towards receiving its Sales License in a timely manner.

If Cannmart receives its Sales License, Cannmart will then operate as one of the first aggregators of medical cannabis, sourced from handpicked ACMPR licensed producers. The Company has identified the need for a competitive landscape where patients have the ability to access a larger variety of medical cannabis strains and oils, without the need to change licensed producers. Through a combination of strategic service and supply agreements, Cannmart will be well-positioned to provide Canadian patients with access to a wide range of medical cannabis products through the most diverse online platform in the Canadian cannabis market. Namaste acquired Cannmart as a late-stage ACMPR applicant, with the intention of creating Canada’s most expansive marketplace for medical cannabis. The receipt of the Production License represents a significant milestone for the Company and will help to propel Namaste to become one of Canada’s leading e-commerce retailer of medical cannabis.

Namaste currently operates one of the largest global e-commerce platforms for cannabis delivery devices and plans to leverage its technology and consumer data with the end goal of acquiring medical patients. In order to facilitate growth at an accelerated rate, the Company plans to utilize its recently launched mobile application under its wholly owned subsidiary, NamasteMD Inc. (“NamasteMD”). This revolutionary medical cannabis app is Canada’s first virtual patient consultation portal to be approved by Apple and Google to be used on both iOS and Android devices. NamasteMD will serve the company as a patient acquisition tool, allowing patients to connect with doctors and nurse practitioners in a safe and secure online environment from the comfort of their homes. NamasteMD was designed to streamline the patient onboarding process in comparison to traditional brick-and-mortar clinics.

With receipt of the production license, Namaste now expects to execute on its overall vision of becoming an all-inclusive online cannabis marketplace and creating a platform that consolidates many of the best product offerings by the top ACMPR Licensed Producers in Canada. Namaste believes it can now deliver on its promise of providing patients with a true “one stop shopping” experience. Namaste will continue creating strategic partnerships through various agreements in attempt to innovate in the Canadian medical cannabis industry.

Further to this news release, Namaste will host a special edition Namaste Live420 on the Company’s YouTube channel via the link below, on Monday, March 19th, 2018 at 8:30 AM EDT to discuss and answer shareholder questions.

https://www.youtube.com/watch?v=TOGWr21c-rE&feature=youtu.be

Management Commentary

Sean Dollinger, President and CEO of Namaste comments; “This important milestone represents an incredible achievement for Namaste and its shareholders. Receipt of the ACMPR Production License not only validates Namaste’s strategy but it serves as a critical component of the Company’s anticipated growth moving forward.  We are very proud to have met our goal of receiving our ACMPR medical cannabis Production License from Health Canada as we look to explore the tremendous opportunities that exist in the Canadian cannabis market. While we are excited with this achievement, management remains highly focused on completing the final protocols set forth by Health Canada and plan on executing the final steps towards receiving our “Sales Only” License.  If the Sales Licence is received, we fully intend on leveraging our data and technology through our global network of operations where we believe we will be well-positioned to implement the same strategy in other legal markets where the Company has established strong market share.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis sales (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771

Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:

namastetechnologies.com

namastevapes.ca

everyonedoesit.ca

namastevaporizers.co.uk

everyonedoesit.co.uk

australianvaporizers.com.au

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.

Tags: , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on BREAKING: Namaste $N.ca $NXTTF Receives ACMPR Medical #Cannabis Production License $ATT.ca $ABCN.ca $ACG.ca $ACB $WEED.ca $HIP.ca

Tetra Bio-Pharma $TBP.ca Announces #FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 8:30 AM on Wednesday, March 14th, 2018

Logo tetrabiopharma rgb web

  • Announced that the U.S. Food and Drug Administration has granted Orphan Drug Designation to the active ingredients of its PPP001 drug for the treatment of complex regional pain syndrome 
  • FDA Orphan Drug Designation program provides orphan status to drugs intended to treat rare diseases or disorders that affect less than 200,000 people in the USA
  • Gives Tetra a seven-year marketing exclusivity, after drug approval by the FDA

OTTAWA, ONTARIO–(March 14, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE:TBP)(OTCQB:TBPMF), today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to the active ingredients of its PPP001 drug (delta-9-tetrahydrocannabinol 9.5% and cannabidiol 2.5%) for the treatment of complex regional pain syndrome (CRPS). The Orphan Drug Designation was granted for the active moiety of the drug PPP001 and not the formulation.

The FDA Orphan Drug Designation program provides orphan status to drugs intended to treat rare diseases or disorders that affect less than 200,000 people in the USA. This designation gives Tetra a seven-year marketing exclusivity, after drug approval by the FDA, and provides Tetra potential incentives such as access to federal grants and tax credits as well as a waiver of Prescription Drug User Fee Act filing fees.

Tetra successfully completed a placebo-controlled Phase 1a and 1b study of PPP001 in healthy volunteers and demonstrated that PPP001 can be safely consumed. “We are pleased to receive FDA Orphan Drug Designation for PPP001 and we look forward to discussing the clinical program with the US FDA that will be used to demonstrate the safety and efficacy in patients suffering from CRPS,” said Guy Chamberland, M.Sc., Ph.D., Chief Scientific Officer of Tetra.

According to the USA National Institute of Health, “complex regional pain syndrome (CRPS) is a chronic pain condition that most often affects one limb (arm, leg, hand, or foot) usually after an injury. CRPS is believed to be caused by damage to, or malfunction of, the peripheral and central nervous systems. CRPS is characterized by prolonged or excessive pain and changes in skin color, temperature, and/or swelling in the affected area.”

Appointment of a New Director – Tetra also announced the appointment of a new Director, Mr. Benoit Chotard, effective immediately. Mr. Chotard was previously a member of the Board of Directors from September 2016 to July 2017, he left for personal reasons, no longer applicable, and is pleased to come back. “We are glad to welcome back Mr. Chotard to the board and we look forward to working closely with him in building Tetra as a leading biopharmaceutical organization,” said Andre Rancourt, Chairman of Tetra Bio-Pharma. “Mr. Chotard’s tremendous experience as an advisor of publicly listed companies will be a huge addition to our team. His local and international network will be a key factor in the Company’s growth.”

Benoit Chotard is a corporate finance & development executive who has over 20 years of international corporate finance, management and public market expertise. Previously, Mr. Chotard was employed as managing partner at Capital Force United, as President & CEO, and Director of Orletto Capital Inc., Vice-president Corporate Development for Pakit Inc., Senior Vice-president Finance Corporate Development and acting as Chief Financial Officer for CANTRONIC Systems (Canada) Inc., Vice-President Chief Financial Officer of Victhom Human Bionics, and spent eight years as Head of the Technology Investment Group of National Bank Financial Inc.

Mr. Chotard has been a Member of “Ordre des ingénieurs du Québec” since 1989 and obtained a bachelor’s degree in Chemical Engineering (1989) and a MBA (1993) from the Université de Sherbrooke.

About PPP001:

PPP001 aims to be the first smokable marihuana for advanced cancer pain under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9.5% THC and 2.5% CBD.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the failure to obtain sufficient financing to execute the Corporation’s business plan; the success of the Rx Princeps™ product offering and inhalation device; guidance on expected sales volumes associated with the Rx Princeps™ product offering and inhalation device; competition; regulation and anticipated and unanticipated costs and delays, and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
(438) 899-7575

For media information, please contact:
Daniel Granger
[email protected]
ACJ Communication
O: 1 514 840 7990 / M: 1 514 232 1556

For investors information, please contact:
[email protected]
(438) 504-5784

Tags: , , , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Announces #FDA Orphan Drug Designation for PPP001 in Treatment of Complex Regional Pain Syndrome $AERO $CBDS $CGRW $APH.ca $GBLX

Marijuana Company of America $MCOA Announces the Offical Launch of Benihemp at the ASD Trade Show $AERO $CBDS $CGRW $APH.ca $GBLX

Posted by AGORACOM-JC at 9:04 AM on Monday, March 12th, 2018

15233 mcoa

  • Announce the official launch of Convenient Hemp Mart, LLC’s “Benihemp” branded CBD products at ASD Market Week,
  • One of the largest business-to-business trade shows in the world.

Escondido, California–(March 12, 2018) – MARIJUANA COMPANY OF AMERICA INC. (OTC Pink: MCOA) (“MCOA” or the “Company“), an innovative hemp and cannabis corporation, is pleased to announce the official launch of Convenient Hemp Mart, LLC’s “Benihemp” branded CBD products at ASD Market Week, one of the largest business-to-business trade shows in the world.

Convenient Hemp Mart has developed a collection of Benihemp branded, sample sized products for consumers including topicals, tinctures, and edibles packaged in 1-day, 2-day, and 30-day supplies. The target markets are convenience stores, smoke shops, gas stations and similar types of retail businesses where CBD commerce has a greater likelihood of generating sales from the impulse buyer at the register.

Convenient Hemp Mart is officially launching the Benihemp product line at ASD Market Week (www.asdonline.com) in Las Vegas, NV. ASD is a comprehensive business-to-business trade show for retail merchandise that annually hosts 45,000 buyers from over 90 countries, representing major department stores, convenience stores, gift shops, grocery stores, and other retail stores. Out of the 45,000 attending the show, 98% of the attendees have purchasing power, and the average buyer spends a total of $82,500 on product orders per show. Benihemp will be located in the lower south hall at booth SL2449.

MCOA has invested $100,000 into Benihemp in exchange for a 25% equity stake in Convenient Hemp Mart, LLC.

Donald Steinberg CEO of MCOA stated “Marijuana Company of America is excited for the opportunity to diversify product distribution into retail markets across the country. We believe in the Convenient Hemp Mart team and their ability to successfully launch Benihemp at ASD.”

“We are eagerly looking forward to the unveiling of the Benihemp brand at this ASD Marketplace event. With the ever-growing Convenience store marketplace hitting a new record of over 140 billion dollars in annual sales last year, we believe this is the perfect place to present the first industrial Hemp derived products developed specifically for this market. Our team has worked very diligently for the launch of the Benihemp brand and are all thrilled that it has finally come to life,” said Sam Girges of Benihemp.

About Marijuana Company of America, Inc.

MCOA is a corporation which participates in: (1) product research and development of legal hemp-based consumer products under the brand name “hempSMART™”, that targets general health and well-being; (2) an affiliate marketing program to promote and sell its legal hemp-based consumer products containing CBD; (3) leasing of real property to separate business entities engaged in the growth and sale of cannabis in those states and jurisdictions where cannabis has been legalized and properly regulated for medicinal and recreations use; and, (4) the expansion of its business into ancillary areas of the legalized cannabis and hemp industry, as the legalized markets and opportunities in this segment mature and develop.

About Our Benihemp Products Containing CBD
The United States Food and Drug Administration (FDA) has not recognized CBD as a safe and effective drug for any indication. Our products containing CBD derived from industrial hemp are not marketed or sold based upon claims that their use is safe and effective treatment for any medical condition as drugs or dietary supplements subject to the FDA’s jurisdiction.

Forward Looking Statements

This news release contains “forward-looking statements” which are not purely historical and may include any statements regarding beliefs, plans, expectations or intentions regarding the future. Such forward-looking statements include, among other things, the development, costs and results of new business opportunities and words such as “anticipate”, “seek”, intend”, “believe”, “estimate”, “expect”, “project”, “plan”, or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the inherent uncertainties associated with new projects, the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based products. These forward-looking statements are made as of the date of this news release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-12G, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission. For more information, please visit www.sec.gov.

For more information, please visit the Company’s websites at:

MarijuanaCompanyofAmerica.com
hempSMART.com
NetworkNewsWires/MCOA

Corporate Communications Contact:

NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
[email protected]

Tags: , , , , , ,
Posted in Marijuana Company of America, Medical Marijuana Stocks | Comments Off on Marijuana Company of America $MCOA Announces the Offical Launch of Benihemp at the ASD Trade Show $AERO $CBDS $CGRW $APH.ca $GBLX

Namaste $N.ca $NXTTF Announces LOI With Inolife R&D to Conduct a Research Study to Evaluate Needle-Free Injection Technologies for Medical Cannabis $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:53 AM on Monday, March 12th, 2018

Nlogo

  • Signed a non-binding LOI with Inolife R&D Inc.
  • To initiate a research study to evaluate applications for Inolife’s proprietary needle-free injectors in the medical cannabis industry

VANCOUVER, British Columbia, March 12, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that it has signed a non-binding LOI with Inolife R&D Inc. (“Inolife”), whereby Namaste and Inolife will negotiate the terms of a definitive agreement (the “Agreement”) to initiate a research study to evaluate applications for Inolife’s proprietary needle-free injectors in the medical cannabis industry. Under the terms of the LOI and proposed Agreement, Namaste will hold exclusive rights to research and distribute Inolife’s needle-free injection technologies for applications in the cannabis industry. Namaste will also participate in Inolife’s anticipated private placement by acquiring up to 10% of the shares issued under the offering. Inolife will also provide Namaste with the right to acquire up to an additional 10% of the shares issued under the offering at the same price. Additionally, Namaste will purchase up to 10% of the shares issued in connection with Inolife’s go-public transaction for approximately $250,000. Namaste believes that Inolife’s needle-free technologies could revolutionize dosage and administration of cannabis for medical purposes.

The LOI and proposed Agreement represent a strategic initiative for Namaste’s continued effort to offer innovative products to the medical cannabis market. Namaste believes that Inolife’s technology provides the most accurate and efficient method for dosing with medical cannabis. Namaste expects to work within Health Canada’s current and future cannabis regulations, when proceeding towards commercialization of pre-filled needle-free syringes. Namaste expects to commercialize the pre-filled needle-free syringes through its wholly owned subsidiary and late-stage applicant under Access to Cannabis for Medical Purposes Regulations (“ACMPR”), Cannmart Inc. The Company also expects to engage with Canadian ACMPR medical cannabis producers to co-brand medical cannabis oil, to be sold and used for applications with Inolife’s technology.

Key Terms of the LOI

  • Namaste will initiate a research study to determine the viability to use Inolife’s needle-free injectors for medical cannabis.
  • Namaste will bear all costs for research and development.
  • Namaste will participate for up to 10% of Inolife’s anticipated private placement and go-public transaction.
  • Namaste will have exclusive rights to distribute Inolife’s products for the purposes of use with medical cannabis.
  • Both parties agree to a 30-day period from the execution date of the LOI to negotiate terms of a definitive agreement and establish a protocol to proceed with a research study.

Management Commentary

Michael Wright, President and CEO of Inolife comments, “We’re very excited about the proposed partnership with Namaste. We feel that Namaste is best positioned to deliver on our strategic plan to become an innovator of delivery systems for the medical cannabis industry. We’re pleased to be the first company, in partnership with Namaste, to explore needle-free device technology in the context of medical cannabis delivery.”

Sean Dollinger, President and CEO of Namaste comments, “We are very pleased to announce this LOI and our expectation of providing research and development of this innovative technology for applications with medical cannabis. We believe that Inolife’s technology could provide the most efficient and accurate method for dosing with medical cannabis. We see a massive opportunity to revolutionize the industry by bringing this exciting technology to the medical cannabis market. We’re delighted to see that industry-leading companies like Inolife are recognizing Namaste for its value in its database, platform and brand.”

About Inolife R&D Inc.
Inolife R&D Inc. is an emerging specialty medical device company focused on developing and commercializing self-administered medical products using novel drug delivery technologies. The company was founded to take advantage of novel techniques of liquid jet and ballistics-based epidermal drug injection that we believe will improve a patient’s quality of life by making medicines easier to self-administer, work better, and remove the anxiety and inconvenience associated with hypodermic needle injections.

About Namaste Technologies Inc.
Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors,

“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:

namastetechnologies.com
namastevapes.ca
everyonedoesit.ca
namastevaporizers.co.uk
everyonedoesit.co.uk
australianvaporizers.com.au

For more information about Inolife R&D Inc. and its products please visit inolifesciences.com
Michael Wright
President, CEO
Direct: 1-866-834-3777
Email: [email protected]

Forward Looking Information
This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.

Tags: , , , , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Announces LOI With Inolife R&D to Conduct a Research Study to Evaluate Needle-Free Injection Technologies for Medical Cannabis $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Namaste $N.ca Announces February 2018 Sales of C$1.37M Representing a 146% Year-Over-Year Increase and Provides Update on #NamasteMD $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:55 AM on Wednesday, March 7th, 2018

Nlogo

  • February 2018 total unaudited net revenue C$1,370,442
  • 146% revenue increase in February 2018 vs. February 2017

VANCOUVER, British Columbia, March 07, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce February 2018 total unaudited net revenue as reported by the Company (including shipping revenues and after discounts and refunds) were C$1,370,442, representing a 146% revenue increase in February 2018 compared with February 2017. February is a historically low month for sales and as such, the Company is pleased with these results. Management anticipates these year-on-year growth trends to continue as the Canadian market moves towards cannabis legalization and the Company executes its strategy to expand sales in emerging markets.

The table below outlines gross sales of Namaste’s major sites and includes site traffic, conversion rates, total number of orders per site and average online basket price.

In addition to announcing its February sales, the Company is pleased to provide an update on its progress with Namaste’s medical cannabis telemedicine application, NamasteMD. During the month of February, management initiated a soft-launch of NamasteMD, which is now available on Apple and Google Android devices. The Company is pleased with initial results, having over 3,000 downloads with a 5-star rating on the Apple Store and a 4.9-star rating on Google Android. The Company, through its soft-launch of NamasteMD has also acquired 375 medical cannabis patients. The Company is now focusing on streamlining the patient acquisition process and further developing the platform. Management anticipates substantial growth in patient acquisition rates for March following a full launch of NamasteMD across the Company’s Canadian platform.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments; “We are very pleased to be seeing the positive trend of monthly sales increases year-over-year. With the Cannmart license pending approval, we are very encouraged to see our hardware business growing, which should have a direct impact on our ability to expand our e-commerce platform to include the sale of cannabis products and shift our focus on aggressive acquisition of patients via NamasteMD. While the soft-launch of NamasteMD has been a success, we feel that obtaining our sales license should substantially increase our ability to convert downloaded users into patients. Our ability to provide patients with an all-inclusive e-commerce marketplace of cannabis products and services in the near term should serve to significantly increase our market share moving forward.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis sales (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors
“Sean Dollinger”
Chief Executive Officer
Direct: +1 (786) 389 9771
Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:
namastetechnologies.com
namastevapes.ca
everyonedoesit.ca
namastevaporizers.co.uk
everyonedoesit.co.uk
australianvaporizers.com.au

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.

 

Tags: , , , , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca Announces February 2018 Sales of C$1.37M Representing a 146% Year-Over-Year Increase and Provides Update on #NamasteMD $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Namaste $N.ca $NXTTF Submits Health Canada ACMPR Affirmation of Readiness $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:49 AM on Monday, March 5th, 2018

Nlogo

  • Company’s wholly owned subsidiary, Cannmart Inc. has submitted its Affirmation of Readiness and video evidence package
  • Purpose of the AOR is to provide evidence to Health Canada that Cannmart has completed construction and fit-up of the facility as per the application
  • AOR represents a significant milestone for the Company in completion of the construction of Cannmart’s facility

VANCOUVER, British Columbia, March 05, 2018 – Namaste Technologies Inc. (“Namaste” or the “Company”) (CSE:N) (FRA:M5BQ) (OTCMKTS:NXTTF) is pleased to announce that the Company’s wholly owned subsidiary, Cannmart Inc. (“Cannmart”) has submitted its Affirmation of Readiness (“AOR”) and video evidence package to Health Canada. Cannmart is a late-stage applicant for a medical cannabis “sales-only” license under Canada’s Access to Cannabis for Medical Purposes Regulation (“ACMPR”). The purpose of the AOR is to provide evidence to Health Canada that Cannmart has completed construction and fit-up of the facility as per the application. Having submitted the AOR, the Company anticipates Health Canada’s review of the evidence package in due course and the issuance of its ACMPR sales license shortly thereafter. The AOR represents a significant milestone for the Company in completion of the construction of Cannmart’s facility.

Management Commentary

Sean Dollinger, President and CEO of Namaste comments; “We are very pleased to have completed construction of Cannmart and submission of the AOR. Namaste is looking forward to launching Cannmart and following through with our strategy to become Canada’s leading innovator in medical cannabis online retail. Thank you to the management team at Cannmart for seeing this project through to completion and we’re looking forward to receiving follow up from Health Canada soon.”

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through 24 e-commerce sites in 20 countries and with distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis sales license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

“Sean Dollinger”

Chief Executive Officer

Direct: +1 (786) 389 9771
Email: [email protected]

Further information on Namaste and its products can be accessed through the links below:

namastetechnologies.com
namastevapes.ca
everyonedoesit.ca
namastevaporizers.co.uk
everyonedoesit.co.uk
australianvaporizers.com.au

Forward Looking Information

This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The Canadian Securities Exchange has neither reviewed nor approved the contents of this press release.

Tags: , , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca $NXTTF Submits Health Canada ACMPR Affirmation of Readiness $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Tetra Bio-Pharma $TBP.ca names #Aphria $APH.ca CFO as Chairman of Audit Committee $AERO $CBDS $CGRW $GBLX

Posted by AGORACOM-JC at 8:50 AM on Monday, February 26th, 2018

Logo tetrabiopharma rgb web

  • Announced changes to its Board of Directors  today, including the appointment of Aphria Inc.’s Chief Financial Officer (CFO), Mr. Carl Merton, as Chair of Tetra’s Audit Committee
  • In addition to his extensive financial background, Mr. Merton is a Chartered Accountant and has served as a past Chair of both the CICBV and the International Association of Professional Business Valuators

OTTAWA, ONTARIO–(Feb. 26, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation“) (TSX VENTURE:TBP)(OTCQB:TBPMF), announced changes to its Board of Directors (the “Board”) today, including the appointment of Aphria Inc.’s Chief Financial Officer (CFO), Mr. Carl Merton, as Chair of Tetra’s Audit Committee.

In addition to his extensive financial background, Mr. Merton is a Chartered Accountant and has served as a past Chair of both the CICBV and the International Association of Professional Business Valuators. Mr. Merton is currently a member of the Board of Directors and Chair of the Audit Committee of Motor City Community Credit Union.

Mr. Merton has served on the Tetra Board since 2016 and brings over 20 years of financial and business experience to the Audit Committee. He replaces Mr. Robert Brouillette, whose resignation was accepted immediately upon the Board becoming aware that a decision had been rendered by a professional regulatory organization against Mr. Brouillette in relation to professional activities unrelated to his responsibilities as a director of Tetra.

Mr. André Rancourt, Tetra’s Chair, was also named to the Audit Committee. Mr. Rancourt also acts as a consultant on several commercial strategy committees including FIA and IRZC. He has significant practical experience that provided him with expertise in many fields, including human and animal natural health products. Over the last ten years, he worked as a consultant to re-organize the operations of companies on behalf of several venture capital investment funds.

“These appointments further strengthen our corporate governance practices,” said Tetra CEO Bernard Fortier. “Both Mr. Merton and Mr. Rancourt have stellar reputations in the capital market and will continue to provide our management team and our entire Board with support and guidance as we embark on the next stage of our growth.”

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Corporation believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Corporation’s ability to control or predict, that may cause the actual results of the Corporation to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, failure to obtain sufficient financing to execute the Corporation’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Corporation’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Corporation’s public disclosure record on file with the relevant securities regulatory authorities. Although the Corporation has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Corporation does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Andre Rancourt
Executive Chairman
[email protected]
(438) 899-7575

Tags: , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca names #Aphria $APH.ca CFO as Chairman of Audit Committee $AERO $CBDS $CGRW $GBLX

The week in #marijuana deals: Emerald online, #ABcann gets clinical and #Wheaton goes to Uruguay $N.ca $ACB.ca $HIP.ca $WEED.ca $CMED.ca $TBP.ca

Posted by AGORACOM-JC at 10:31 AM on Monday, February 5th, 2018

  • Namaste Technologies Inc. and B.C.-based LP Emerald Health Therapeutics Inc., announced on Tuesday that they were joining forces to develop a new e-commerce platform for Emerald products.
  • Emerald will use Namaste’s online technology to sell its cannabis alongside Namaste’s catalogue of “cannabis delivery devices.

Aphria Inc.’s announcement on Monday morning that it was buying little-known Nuuvera Inc. for an implied value of $826 million kicked the week off with a bang. By Friday, however, optimism in the sector had hit a wall. The Canadian Marijuana Index shed more than 30 per cent between Monday and Friday, and the week ended with a volatile day of sell-offs and opportunistic buys. While the cannabis stock market shuddered, companies continued to make deals. Here are a few you may have missed.

Emerald Goes Online

Namaste Technologies Inc., an online retailer of cannabis related products, and B.C.-based LP Emerald Health Therapeutics Inc., announced on Tuesday that they were joining forces to develop a new e-commerce platform for Emerald products. Emerald will use Namaste’s online technology to sell its cannabis alongside Namaste’s catalogue of “cannabis delivery devices.” Emerald will also provide product to Namaste’s subsidiary Cannmart Inc., which is currently applying for a sales-only licence under the ACMPR. Under the deal, the companies will each get 500,000 warrants for the other’s stocks.

Getting Clinical

On Thursday, licensed producer ABcann Global Corp. completed its acquisition of Harvest Medicine Inc., a medical cannabis clinic in Calgary with 9,700 patients, according to the company. ABcann plans to develop additional Harvest Medicine clinics, starting with one in Edmonton that’s expected to open this spring. It paid $1.5 million in cash and issued 1,056,338 shares to Harvest Medicine owners, with more promised if the company hits “certain performance milestones.”

Other deals

Winnipeg-based LP Delta 9 Cannabis Inc., which produces cannabis inside “grow pods” made of repurposed shipping containers, plans to develop a production facility in Southern Alberta with private company Westleaf Cannabis Inc. On Monday the companies announced they had signed a non-binding letter of intent to repurpose an existing building into an operation intended to produce 4,000 kilograms of dried flower a year. Each company will take a 50 per cent stake in the project, which, according to Delta 9, is expected to be up and running as early as Q3 2018.

Cannabis Wheaton Income Corp. entered into an agreement to buy Uruguay-based Inverell S.A. The federally licensed “cannabis operator,” based in Uruguay’s capital Montevideo, has 16 hectares planted and another 574 hectares available for cultivation, according to a press release from Wheaton Income. Wheaton Income is paying around $5.5 million in cash and shares, and another $9.5 million if Inverell hits certain goals.

iAnthus Capital Holdings Inc., which is based in the U.S. but trades on the Canadian Securities Exchange, acquired New York-based Citiva Medical for US$18 million in cash and shares. Citiva holds one of only 10 medical marijuana licences in New York, and plans to open four dispensaries over the next two years. According to Canaccord Genuity Corp. analyst Matt Bottomley, New York’s medical cannabis market could be worth up to $1 billion annually. There are still concerns, however, about how Canadian regulators will deal with Canadian-listed companies operating in the U.S. where the federal government recently announced its intent to enforce cannabis laws more strictly.

Source: http://business.financialpost.com/investing/the-week-in-marijuana-deals-emerald-online-abcann-gets-clinical-and-wheaton-goes-to-uruguay

Tags: , , ,
Posted in All Recent Posts, Featured, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on The week in #marijuana deals: Emerald online, #ABcann gets clinical and #Wheaton goes to Uruguay $N.ca $ACB.ca $HIP.ca $WEED.ca $CMED.ca $TBP.ca

Tetra Bio-Pharma $TBP.ca Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 8:45 AM on Monday, February 5th, 2018

Logo tetrabiopharma rgb web

  • Received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD) Health Canada to its Clinical trial application  for the Company’s PPP001 prescription smokable dried cannabis product
  • Coinciding with World Cancer Day 2018, Tetra is now ready to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patients, the first registration trial in the world for smokable cannabinoid-based drug

OTTAWA, ONTARIO–(Feb. 4, 2018) – Tetra Bio-Pharma Inc. (“Tetra” or the “Company“) (TSX VENTURE:TBP)(OTCQB:TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to announce that it has received a No Objection Letter (NOL) from the Therapeutic Products Directorate (TPD) Health Canada to its Clinical trial application (CTA) for the Company’s PPP001 prescription smokable dried cannabis product.

Coinciding with World Cancer Day 2018, Tetra is now ready to initiate its Phase 3 clinical trial of PPP001 in terminal cancer patients, the first registration trial in the world for smokable cannabinoid-based drug. This trial is expected to be a landmark study, enrolling a total of 946 subjects, evaluating the therapeutic benefits of a cannabinoid prescription drug in improving quality of life and treating pain in terminal cancer patients.

“This is an especially significant and noteworthy milestone for the lead candidate in our product pipeline,” said Bernard Fortier, Tetra’s CEO, “as it positions Tetra to potentially be the first company with a Health Canada approved, cannabinoid-based drug on the market aimed at treating breakthrough pain in cancer patients. The advanced cancer pain market is a $2.4B market1; this is a significant and important opportunity for the Company as our drug PPP001 has the potential to help reduce the reliance on opioids for the management of severe pain.”

The first and main recruitment center of the trial will be in Montreal at Santé Cannabis, Québec’s first medical clinic and resource centre specializing in cannabis and cannabinoids for medical purposes.

The PPP001 Phase 3 trial will evaluate the effects of Tetra’s smokable cannabinoid-based drug made from natural dried cannabis. Tetra previously entered into a supply agreement with Aphria Inc., to use Aphria’s unique blend of dried medical cannabis in its PPP001 clinical trial. Aphria owns an 8.5% stake in Tetra.

As part of the clinical trial, Tetra will also collect the pharmaco-economics evidence required from insurers in order to support the reimbursement of the first cannabis prescription drug. “Today, most private insurance plans do not cover cannabis treatment, nor is public reimbursement available, making this therapeutic option costly for patients. It is very important for us to bring a new therapeutic option for patients in the form of an approved prescription drug and to take action in order to have it reimbursed for patients” commented Bernard Fortier, CEO.

The trial aims to demonstrate that PPP001 eases suffering and facilitates a more serene experience of living and dying in terminal cancer patients. If conclusive, Tetra will submit a filing for a Drug Identification Number (DIN) to Health Canada in 2019, thus providing a new noninvasive treatment to relieve pain for cancer patient. With this approval, Tetra expects to be on time with its previously announced schedule with the development of PPP001, culminating in a potential launch in Canada by Q1, 2020 and in the US by Q3, 2020.

Dr Guy Chamberland, Tetra’s Chief Scientific Officer (CSO) explained that: “The development of PPP001 for patients with advanced cancer is an important commitment for Tetra, given that cancer patients suffer from severe pain which is often accompanied by depression and insomnia. Medical cannabis has been shown to help patients beyond the immediate benefit of pain relief.”

“With the expertise of Santé Cannabis, we expect to demonstrate the clinical benefits of PPP001 on the quality of life of advanced cancer patients. It’s important to note that our clinical program will also address the potential of PPP001 to reduce the reliance on opioids for management of severe pain. We expect that, once it is approved as a drug under prescription, PPP001 will be included over time ahead of opioids treatment for those patients with terminal cancer pain. The Company will continue to maintain a transparent and direct line of communication with Health Canada and the U.S. FDA to ensure that we address the issues required for drug approval. PPP001 is about patients first, ” added Dr. Guy Chamberland.

Tetra worked with Santé Cannabis physicians to design a clinical trial that would demonstrate the safety and efficacy of PPP001 in terminal cancer patients and have focused the clinical development on a first indication in patients with advanced cancer. The Phase III clinical trial will be performed by the medical team of Santé Cannabis.

“Throughout my clinical experience assessing and following more than 600 medical cannabis patients, cannabis inhalation remains a critical option to provide rapid relief from a wide variety of symptoms associated with advanced cancer, ” said Dr. Antonio Vigano, Principal Investigator of the trial and Research Director of Santé Cannabis. “We will rigorously assess the safety, efficacy and tolerability of PPP001 to support the population of cancer patients by bringing an important therapeutic tool to the same standard of prescription drugs It is great to be celebrating World Cancer Day 2018 with the first large scale clinical study to prove that medical cannabis can ease the suffering and improve quality of life of many cancer patients, particularly when they most need it.”

About Cancer Pain:

In the USA, 1,5 million patients suffer from cancer pain2. Pain is one of the most frightening of all cancer symptoms for patients and their families3. According to statistics published by the American Cancer Society in 20024, 50% to 70% of people with cancer experience some degree of pain, with a quarter of them actually dying in pain. Without adequate relief of their pain, their quality of life is negatively impacted. Furthermore, the incidence of pain in advanced stages of invasive cancer approaches 80% and it is 90% in patients with bone metastases5.

  1. https://decisionresourcesgroup.com/report/141466-biopharma-cancer-pain-2015
  2. Melnikova I. Pain market 2010 ;, doi:10.1038/nrd3226
  3. Winslow M, Seymour J, Clark D. 2005. Stories of cancer pain: a historical perspective. J Pain Symptom Manage, 29:22-31.
  4. American Cancer Society. 2002. Cancer facts and figures 2002 
  5. Pharo GH, Zhou L. 2005. Pharmacologic Management of Cancer Pain. JAOA, 105:S21-28.

About PPP001:

PPP001 aims to be the first smokable marihuana for advanced cancer pain under prescription. It is a dried cannabis pellet designed to be smoked in an inhalation device specifically developed for this product. PPP001 is a unique blend of 3 strains of standardized dried cannabis, creating a drug substance with 9,5% THC and 2,5% CBD.

About Aphria:

Aphria Inc., one of Canada’s lowest cost producers, produces, supplies and sells medical cannabis. Located in Leamington, Ontario, the greenhouse capital of Canada, Aphria is truly powered by sunlight, allowing for the most natural growing conditions available. Aphria is committed to providing pharma-grade medical cannabis, superior patient care while balancing patient economics and returns to shareholders.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TSX VENTURE:TBP)(OTCQB:TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and clinical development. Tetra is focusing on three core business pillars: clinical research, pharmaceutical promotion and retail commercialization of cannabinoid-based products.

More information at: www.tetrabiopharma.com

Source: Tetra Bio-Pharma

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

Forward-looking statements

Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address activities, events or developments that the Company believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding potential acquisitions and financings) are forward-looking statements. Forward-looking statements are generally identifiable by use of the words “may”, “will”, “should”, “continue”, “expect”, “anticipate”, “estimate”, “believe”, “intend”, “plan” or “project” or the negative of these words or other variations on these words or comparable terminology. Forward-looking statements are subject to a number of risks and uncertainties, many of which are beyond the Company’s ability to control or predict, that may cause the actual results of the Company to differ materially from those discussed in the forward-looking statements. Factors that could cause actual results or events to differ materially from current expectations include, among other things, without limitation, the inability of the Company, through its wholly-owned subsidiary, GrowPros MMP Inc., to obtain a license for the production of medical marijuana; failure to obtain sufficient financing to execute the Company’s business plan; competition; regulation and anticipated and unanticipated costs and delays, the success of the Company’s research strategies, the applicability of the discoveries made therein, the successful and timely completion and uncertainties related to the regulatory process, the timing of clinical trials, the timing and outcomes of regulatory or intellectual property decisions and other risks disclosed in the Company’s public disclosure record on file with the relevant securities regulatory authorities. Although the Company has attempted to identify important factors that could cause actual results or events to differ materially from those described in forward-looking statements, there may be other factors that cause results or events not to be as anticipated, estimated or intended. Readers should not place undue reliance on forward-looking statements. While no definitive documentation has yet been signed by the parties and there is no certainty that such documentation will be signed The forward-looking statements included in this news release are made as of the date of this news release and the Company does not undertake an obligation to publicly update such forward-looking statements to reflect new information, subsequent events or otherwise unless required by applicable securities legislation.

Tetra Bio-Pharma Inc.
Dr. Anne-Sophie Courtois, DVM
Vice President, Marketing & Communications
[email protected]
(514) 360-8040 Ext. 210

For media information, please contact :
Daniel Granger
[email protected]
ACJ Communication
O: 1 514 840 7990 / M: 1 514 232 1556

Tags: , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Tetra Bio-Pharma Inc. | Comments Off on Tetra Bio-Pharma $TBP.ca Receives Health Canada Phase 3 Clinical Trial Approval For Smokable Dried Cannabis Prescription Drug $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Namaste $N.ca Announces Increase in Bought Deal Offering to $35 Million $ACB.ca $HIP.ca $WEED.ca $CMED.ca

Posted by AGORACOM-JC at 12:05 PM on Thursday, February 1st, 2018

Nlogo

  • Now agreed to purchase 13,726,000 units of the Company on a “bought deal” basis
  • At a price per Unit of $2.55 for gross proceeds of $35,001,300

VANCOUVER, BRITISH COLUMBIA–(Feb. 1, 2018) – NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES

Namaste Technologies Inc. (CSE:N)(CSE:N.CN)(CNSX:N)(FRANKFURT:M5BQ)(OTCQB:NXTTF) (“Namaste” or the “Company“), is pleased to announce that it has entered into an amended letter of engagement with Eight Capital and Canaccord Genuity Corp. as co-lead underwriters and joint bookrunners, and including Beacon Securities Limited (together, the “Underwriters”), under which the Underwriters have now agreed to purchase 13,726,000 units of the Company (the “Units“), on a “bought deal” basis pursuant to a filing of a short form prospectus, subject to all required regulatory approvals, at a price per Unit of $2.55 (the “Issue Price“) for gross proceeds of $35,001,300 (the “Offering“).

The Company has agreed to grant the Underwriters an over-allotment option to purchase up to an additional 15% of the Units at the Issue Price, exercisable in whole or in part, at any time on or prior to the date that is 30 days following the closing of the Offering. If this option is exercised in full, an additional approximately $5,250,195 will be raised pursuant to the Offering and the aggregate proceeds of the Offering will be approximately $40,251,495.

Each Unit will be comprised of one common share of the Company (a “Common Share“) and one Common Share purchase warrant (a “Warrant“). Each Warrant shall entitle the holder thereof to purchase one Common Share at an exercise price of $3.15, for a period of 24 months following the closing of the Offering. If, following the closing of the Offering, the volume weighted average price of the Common Shares on the Canadian Securities Exchange is equal to or greater than $6.00 for any 10 consecutive trading days, the Company may, upon providing written notice to the holders of Warrants, accelerate the expiry date of the Warrants to the date that is 30 days following the date of such written notice.

The Company intends to use the net proceeds of the Offering to fund inventory and for working capital and general corporate purposes.

The closing date of the Offering is scheduled to be on or about February 27, 2018 and is subject to certain conditions including, but not limited to, the receipt of all necessary approvals, including the approval of the Canadian Securities Exchange and the applicable securities regulatory authorities.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful. The securities being offered have not been, nor will they be, registered under the United States Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the United States Securities Act of 1933, as amended, and applicable state securities laws.

About Namaste Technologies Inc.

Namaste is the largest online retailer for medical cannabis delivery systems globally. Namaste distributes vaporizers and smoking accessories through e-commerce sites in 26 countries and with 5 distribution hubs located around the world. Namaste has majority market share in Europe and Australia, with operations in the UK, Canada and Germany and has opened new supply channels into emerging markets including Brazil, Mexico and Chile. Namaste, through its acquisition of Cannmart Inc., a Canadian based late-stage applicant for a medical cannabis distribution license (under the ACMPR Program) is pursuing a new revenue vertical in online retail of medical cannabis in the Canadian market. Namaste intends to leverage its existing database of Canadian medical cannabis consumers, along with its expertise in e-commerce to create an online marketplace for medical cannabis patients, offering a larger variety of product and a better user experience.

On behalf of the Board of Directors

Sean Dollinger, Chief Executive Officer

Further information on the Company and its products can be accessed through the links below:

www.namastetechnologies.com

www.namastevaporizers.co.uk

www.everyonedoesit.co.uk

Forward-Looking Information

FORWARD-LOOKING INFORMATION This press release contains forward-looking information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Although such statements are based on management’s reasonable assumptions, Namaste assumes no responsibility to update or revise forward-looking information to reflect new events or circumstances unless required by law. Although the Company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, undue reliance should not be placed on the forward-looking statements because the Company can give no assurance that they will prove to be correct. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. These statements speak only as of the date of this press release. Actual results could differ materially from those currently anticipated due to a number of factors and risks including various risk factors discussed in the Company’s disclosure documents, which can be found under the Company’s profile on www.sedar.com. This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward looking statements are made pursuant to the safe harbour provisions of the Private Securities Litigation Reform Act of 1995. The CSE has neither reviewed nor approved the contents of this press release.

Namaste Technologies Inc.
Sean Dollinger
Chief Executive Officer
+1 (786) 389 9771
[email protected]

Tags: , , , , ,
Posted in All Recent Posts, Medical Marijuana Stocks, Namaste Technologies Inc. | Comments Off on Namaste $N.ca Announces Increase in Bought Deal Offering to $35 Million $ACB.ca $HIP.ca $WEED.ca $CMED.ca

« Older Entries
Newer Entries »